Drug Profile
Research programme: integrin inhibitors - Aviara Pharmaceuticals
Alternative Names: AVA 3486; α4β7 integrin inhibitor - Aviara PharmaceuticalsLatest Information Update: 28 Feb 2021
Price :
$50
*
At a glance
- Originator Aviara Pharmaceuticals
- Class Small molecules
- Mechanism of Action Alpha4beta7 integrin antagonists; Integrin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Dry eyes; Inflammatory bowel diseases
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for preclinical development in Dry-eyes in USA (Topical)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in USA (PO)
- 28 Feb 2021 No recent reports of development identified for research development in Cancer in USA